TIBBIYOT TA’LIMI VA INNOVATSIYALARI · Oct 20, 2026
Innovative approaches to early and preclinical diagnosis of Alzheimer's disease: fluid biomarkers, neuroimaging, and digital technologies
By Amirova MTQ, Butunboyeva MQQ, Shevketova DI et al.
Alzheimer's disease is one of the most common causes of dementia and is characterized by progressive decline in cognitive functions and neurodegenerative changes in brain tissue. Early detection of the disease, assessment of biological processes before clinical symptoms become clearly apparent, and refinement of individual prognosis are important tasks in modern neurology. This article analyzes modern diagnostic approaches aimed at detecting Alzheimer's disease at early and preclinical stages based on the scientific literature. The diagnostic capabilities of biomarkers such as amyloid-beta, phosphorylated tau proteins, neurofilament light chain, and glial fibrillary acidic protein in blood plasma and cerebrospinal fluid are highlighted. The roles of magnetic resonance imaging, amyloid and tau positron emission tomography, and digital diagnostic technologies based on artificial intelligence are also reviewed. The results of the analysis indicate that the combined use of different diagnostic methods may expand the ability to detect disease-related biological changes. However, diagnostic accuracy, cost-effectiveness, existing limitations, and ethical requirements must be considered when introducing them into clinical practice.